Champions Biotechnology UK Subsidiary sets up its base at the London BioScience Innovation Centre
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a US company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a UK subsidiary, Champions Biotechnology UK Ltd. (CBUK), at the London BioScience Innovation Centre and in order to expand its personalized Oncology Business.
Guy Malchi, MBA, General Manager of Champions Biotechnology UK Ltd. comments; “Since its foundation a year ago, we have been experiencing an increase in our personalized oncology activity outside the US, especially in the UK. This growth stems from leading oncologists in Europe, as they recognize the benefits to their practice of using our services. In joining LBIC and its network of partners, Champions Biotechnology UK Ltd. will enable our services to be accessible to many more physicians and patients in Europe and beyond and a central London location is important in terms of accessing both clients and partners within the sector.
Dr Ken Larkin, Deputy CEO of the London BioScience Innovation Centre (LBIC) comments; “we are delighted that CBUK has chosen to establish a UK subsidiary at LBIC. CBUK joins a growing community of international bioscience companies benefiting from our strategic central London location, links to Europe and collaborative links and benefits provided by the Royal Veterinary College.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company was co-founded by David Sidransky, MD who with Manuel Hidalgo, MD, Ph.D. developed the Company’s Preclinical Platform; a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts™) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through preclinical development, the Company intends to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to Companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.